Standardised Herbal Extracts Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

The licence and approval architecture for standardised herbal extracts manufacturing in India operates across two primary regulatory frameworks: the FSSAI framework for food and nutraceutical applications, and the CDSCO-AYUSH framework for pharmaceutical and therapeutic claims. A bankable DPR must address both pathways depending on target market mix, with specific attention to the BIS standards for herbal preparations and the Pollution Control Committee requirements under the EIA Notification 2006.

• FSSAI State/Central Licence under the Food Safety and Standards Act 2006: Required for extracts used in supplements, functional foods, and beverages. The licence is mandated when annual turnover exceeds ₹12 lakh; for export-oriented units, FSSAI export licence covers both domestic compliance and destination market requirements. Manufacturing premises must comply with Schedule 4 requirements and the specific provisions for 'Proprietary Food' notifications.
• CDSCO Manufacturing Licence under the Drugs and Cosmetics Act 1940: Required if the herbal extract will be sold as a 'drug' under Section 3(b)(i) or (ii) with therapeutic claims. Central or State Licensing Authority (CLA/SLA) issues Form 25 (for allopathic) or the applicable AYUSH form for Ayurvedic, Siddha, or Unani formulations. The applicant must hold a valid drug licence before commencing commercial production.
• Schedule M and Schedule M-III Compliance: The Good Manufacturing Practice (GMP) requirements under Schedule M apply to pharmaceutical grade extracts. Schedule M-III specifically addresses Ayurvedic, Siddha, and Unani medicines, mandating quality control laboratories, standard operating procedures for each manufacturing stage, and documentation of batch records. NABCB-accredited laboratory testing is mandatory for each batch release.
• BIS Certification under the Bureau of Indian Standards Act 2015: While not universally mandatory for all herbal extracts, BIS standards such as IS 15475 for amla extracts and IS 13344 for turmeric extracts provide market credibility and are increasingly specified by pharmaceutical customers in quality agreements.
• AYUSH Premium Mark Certification: Operated by the Quality Council of India under the AYUSH Ministry, this certification signals compliance with elevated quality parameters for botanical preparations. Large retail pharmacy chains and hospital procurement departments increasingly require AYUSH Premium Mark for formulary inclusion.
• Pollution Control Board Consent under the Water (Prevention and Control of Pollution) Act 1974 and Air (Prevention and Control of Pollution) Act 1981: Solvent-based extraction processes require CTO (Consent to Operate) from the State Pollution Control Board. An application under the EIA Notification 2006 (Schedule SI category) is mandatory for projects with solvent consumption above defined thresholds.
• GST Registration and GSTN Compliance: Normal GST registration applies for domestic sales at 5% GST for herbal extracts under HSN 1301. Registered players must maintain e-way bill generation capability and GSTN-compliant invoicing for inter-state movement of botanical raw materials and finished extracts.
• MSME Udyam Registration and PLI Eligibility: If the project qualifies as a micro, small, or medium enterprise under the MSME Development Act 2006, Udyam registration enables access to CGTMSE credit guarantees, MUDRA loan schemes, and state-level MSME subsidies. For projects targeting pharmaceutical exports, eligibility under the PLI scheme for bulk drugs and medical devices may apply if the extract qualifies as a critical intermediate.

KAMRIT Financial Services LLP manages the end-to-end regulatory filing process for the Standardised Herbal Extracts DPR, coordinating FSSAI licence applications, CDSCO drug licence filings, Schedule M compliance documentation, and Pollution Control Board consents across relevant state authorities. Our team maintains active liaison with Central Drugs Standard Control Organization (CDSCO) regional offices, state FDA authorities in Gujarat, Himachal Pradesh, Kerala, and Karnataka, and the Pollution Control Committees in designated industrial zones. The firm also handles BIS certification applications, AYUSH Premium Mark filings, and coordinates with NABCB-accredited testing laboratories for batch certification protocols.

The standardised herbal extracts sub-sector occupies a distinct position within the broader pharmaceuticals market, differentiated from active pharmaceutical ingredients (APIs) by its reliance on botanical raw materials, phytochemical consistency requirements, and dual regulatory pathways through FSSAI and CDSCO. Unlike bulk drugs manufacturing which operates primarily under Schedule M and CDSCO oversight, herbal extracts producers must manage agricultural supply chains, seasonal variations in active marker content, and the AYUSH quality framework for products claiming traditional medicine benefits. The market segments by application: nutraceuticals and dietary supplements constitute the fastest-growing segment at approximately 19-21% CAGR, driven by lifestyle disease prevention awareness; pharmaceutical excipients and botanical drug substances grow at 14-16% CAGR, supported by the chronic disease burden and US generics export opportunity for validated herbal actives; functional food and beverage applications expand at 16-18% CAGR, reflecting consumer preference for clean-label products; and cosmeceuticals represent a 12-15% CAGR opportunity at the premium end of the market.

Key growth gradients emerge across product categories: curcuminoids (from turmeric, grown primarily in Erode and Sangli clusters) demonstrate the most mature standardized extract market with established pricing benchmarks; ashwagandha and bacopa extracts target the adaptogens segment with 25%+ growth driven by stress and cognitive health awareness; and extracts such as Garcinia cambogia and green coffee bean serve the weight management sub-segment with higher margins but greater regulatory scrutiny under FSSAI claims frameworks. The herbal extracts segment differs fundamentally from adjacent categories like synthetic API manufacturing in requiring cold-chain capable warehousing, analytical testing infrastructure for marker compound consistency, and procurement relationships with farmer producer organizations (FPOs) or contract cultivators in defined agro-climatic zones.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

The technology selection for a standardised herbal extracts facility must balance CapEx efficiency against product quality consistency, which directly determines pricing realisation and customer retention in the pharmaceutical and nutraceutical channels. The core extraction technologies available include: maceration and percolation systems, which represent the lowest CapEx entry at ₹15-25 lakh for a 500 kg/day batch vessel but suffer from inconsistent extraction efficiency and higher solvent consumption; counter-current extractors, which offer 85-92% extraction efficiency at moderate CapEx of ₹45-75 lakh per vessel train and represent the preferred technology for turmeric, ashwagandha, and ginger extracts; supercritical CO2 extraction systems, which command ₹1.5-4 crore for a 100 L vessel but produce solvent-free extracts with superior marker compound preservation suitable for premium pharmaceutical applications; and ultrasonic-assisted extraction, which reduces extraction time by 40-60% and solvent consumption by 25-30% compared to conventional methods, with Indian-manufactured ultrasonicators available from suppliers in Mumbai and Pune at ₹20-50 lakh per unit. The downstream processing line determines product form factor and margin profile: spray dryers (from suppliers such as Jay Process Equipment in Ahmedabad or Suan Farfarg in Germany for premium applications) cost ₹60 lakh to ₹1.8 crore depending on capacity and atomisation technology, producing powder extracts with 3-5% moisture content suitable for capsule and tablet manufacturing; freeze dryers maintain higher phytochemical integrity for heat-sensitive extracts but carry 3-4x higher operating cost per kg of output; and liquid extracts in glycerin or alcohol carriers serve the tincture and functional beverage markets at lower processing cost.

The dryer selection is particularly CapEx-critical: a 500 kg/hour spray dryer suitable for a mid-scale operation costs ₹1.2-1.8 crore, whereas a 200 kg/hour unit costs ₹55-80 lakh. Energy benchmarks for a ₹12 crore extraction facility indicate electricity consumption of 180-220 kW peak demand with DG backup requirement, and thermal energy of 400-600 kg/hour of steam from biomass or gas-fired boilers at ₹3.5-4.5 per kWh industrial tariff. Raw material yield benchmarks vary by botanical: turmeric root yields 3.5-6% extract with 95% curcuminoid marker; ashwagandha root yields 1.5-3.5% with withanolide marker; and green tea leaf yields 15-25% catechins.

Conversion cost per kg of finished extract ranges from ₹180-320 for commodity extracts (turmeric, ginger) to ₹600-1,200 for high-purity standardised extracts (bacopa, curcumin at 95%+).

For a standardised herbal extracts project at ₹1.8 crore - ₹28 crore CapEx with a 3.3 - 5.1-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 25-35% promoter equity and 65-75% debt. The primary lender pool for this scale is SIDBI MSME term loan, CGTMSE collateral-free up to ₹5 cr, MUDRA Tarun. The applicable overlay schemes that materially compress effective cost-of-capital are state MSME interest subsidy schemes, PMEGP, women entrepreneur preferential rates. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

For standardised herbal extracts at ₹1.8 crore - ₹28 crore CapEx and 3.3 - 5.1-year payback, the three risks KAMRIT structures mitigation around are demand-side execution risk, input-cost volatility, and regulatory-delay risk. For this category specifically, KAMRIT also models supplier concentration risk, currency exposure where input-imports exceed 25 percent of CapEx, and the working-capital cycle stretch in the first 18 months of commissioning. The Bankable DPR contains the full three-scenario sensitivity (base / bull / bear) on revenue, gross margin, and CapEx that a credit committee needs to see.